Symmetric Dimethylarginine Is Not Associated with Cumulative Inflammatory Load or Classical Cardiovascular Risk Factors in Rheumatoid Arthritis: A 6-Year Follow-Up Study

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Dimitroulas, Theodoros ^a   Hodson, James ^b   Sandoo, Aamer ^a,c   Smith, Jacqueline P ^a   Douglas, Karen M ^a   Kitas, George D ^a,d  

^a RUSSELLS HALL HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c BANGOR UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 N,N' DIMETHYLARGININE; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; CREATININE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ARGININE; CYTOKINE;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DAS28; DIABETES MELLITUS; DISEASE ACTIVITY SCORE; DISEASE ASSOCIATION; DISEASE DURATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; GLOMERULUS FILTRATION RATE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE INSULIN SENSITIVITY CHECK INDEX; REYNOLDS RISK SCORE; RHEUMATOID ARTHRITIS; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR;

AGED; AREA UNDER CURVE; ARGININE; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84946099769     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/796562     Document Type: Article

References (47)

1. S. E. Gabriel, "Why do people with rheumatoid arthritis still die prematurely?" Annals of the Rheumatic Diseases, vol. 67, supplement 3, pp. iii30-iii34, 2008.
2. J. A. Avina-Zubieta, J. Thomas, M. Sadatsafavi, A. J. Lehman, and D. Lacaille, "Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies," Annals of the Rheumatic Diseases, vol. 71, no. 9, pp. 1524-1529, 2012.
3. J. Willers and A. Hahn, "Cardiovascular risk in patients with rheumatoid arthritis: assessment of several traditional risk parameters and a German risk score model," Rheumatology International, vol. 32, no. 12, pp. 3741-3749, 2012.
4. F. Khan, "Assessment of endothelial function as a marker of cardiovascular risk in patients with rheumatoid arthritis," International Journal of Rheumatic Diseases, vol. 13, no. 3, pp. 189-195, 2010.
5. A. Sandoo, J. J. C. S. Veldhuijzen van Zanten, G. S. Metsios, D. Carroll, and G. D. Kitas, "Vascular function andmorphology in rheumatoid arthritis: a systematic review," Rheumatology, vol. 50, no. 11, pp. 2125-2139, 2011.
6. R. H. Böger, R. Maas, F. Schulze, and E. Schwedhelm, "Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-an update on patient populations with a wide range of cardiovascular risk," Pharmacological Research, vol. 60, no. 6, pp. 481-487, 2009.
7. R. H. Böger, L. M. Sullivan, E. Schwedhelm et al., "Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community," Circulation, vol. 119, no. 12, pp. 1592-1600, 2009.
8. F. Schulze, A. M. Carter, E. Schwedhelm et al., "Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke," Atherosclerosis, vol. 208, no. 2, pp. 518-523, 2010.
9. A. Meinitzer, J. T. Kielstein, S. Pilz et al., "Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the ludwigshafen risk and cardiovascular health study," Clinical Chemistry, vol. 57, no. 1, pp. 112-121, 2011.
10. E. Schwedhelm, H. Wallaschofski, D. Atzler et al., "Incidence of all-cause and cardiovascular mortality predicted by symmetric dimethylarginine in the population-based study of health in Pomerania," PLoS ONE, vol. 9, no. 5, Article ID e96875, 2014.
11. + carrier hCAT-2B," Nitric Oxide, vol. 1, no. 1, pp. 65-73, 1997.
12. S. M. Bode-Böger, F. Scalera, J. T. Kielstein et al., "Symmetrical dimethylarginine: a newcombined parameter for renal function and extent of coronary artery disease," Journal of the American Society of Nephrology, vol. 17, no. 4, pp. 1128-1134, 2006.
13. E. Schepers, G. Glorieux, A. Dhondt, L. Leybaert, and R. Vanholder, "Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes," Nephrology Dialysis Transplantation, vol. 24, no. 5, pp. 1429-1435, 2009.
14. E. Schepers, D. V. Barreto, S. Liabeuf et al., "Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease," Clinical Journal of the American Society of Nephrology, vol. 6, no. 10, pp. 2374-2383, 2011.
15. A. Sandoo and G. D. Kitas, "Current perspectives on the assessment of vascular function andmorphology in rheumatoid arthritis," International Journal of Clinical Rheumatology, vol. 8, no. 1, pp. 1-3, 2013.
16. V. F. Panoulas, K.M. J. Douglas, H. J. Milionis et al., "Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis," Rheumatology, vol. 46, no. 9, pp. 1477-1482, 2007.
17. A. Sandoo, T. Dimitroulas, J. Hodson, J. P. Smith, K.M. Douglas, and G. D. Kitas, "Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoid arthritis: a 6 year follow-up study," Rheumatology, 2014.
18. F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis," Arthritis & Rheumatism, vol. 31, no. 3, pp. 315-324, 1988.
19. M. L. L. Prevoo, M. A. Van't Hof, H. H. Kuper, M. A. van Leeuwen, L. B. A. van de Putte, and P. L. C. M. van Riel, "Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis," Arthritis & Rheumatism, vol. 38, no. 1, pp. 44-48, 1995.
20. J. R. Kirwan and J. S. Reeback, "Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis," British Journal of Rheumatology, vol. 25, no. 2, pp. 206-209, 1986.
21. Z. Radikova, "Assessment of insulin sensitivity/resistance in epidemiological studies," Endocrine Regulations, vol. 37, no. 3, pp. 189-194, 2003.
22. A. Katz, S. S. Nambi, K. Mather et al., "Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans," Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 7, pp. 2402-2410, 2000.
23. M. A. Gonzalez-Gay, C. Gonzalez-Juanatey, A. Piñeiro, C. Garcia-Porrua, A. Testa, and J. Llorca, "High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis," The Journal of Rheumatology, vol. 32, no. 7, pp. 1219-1223, 2005.
24. H. Maradit-Kremers, P. J. Nicola, C. S. Crowson, K. V. Ballman, and S. E. Gabriel, "Cardiovascular death in rheumatoid arthritis: a population-based study," Arthritis & Rheumatism, vol. 52, no. 3, pp. 722-732, 2005.
25. E. Klimek, A. Skalska, B. Kwas̈ny-Krochin et al., "Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration," Mediators of Inflammation, vol. 2014, Article ID681635, 11pages, 2014.
26. L. Kozera, J. Andrews, and A. W. Morgan, "Cardiovascular risk and rheumatoid arthritis-the next step: differentiating true soluble biomarkers of cardiovascular risk from surrogate measures of inflammation," Rheumatology, vol. 50, no. 11, pp. 1944-1954, 2011.
27. B. Kwas̈ny-Krochin, P. Głuszko, and A. Undas, "Plasma asymmetric dimethylarginine in active rheumatoid arthritis: links with oxidative stress and inflammation," Polskie Archiwum Medycyny Wewnetrznej, vol. 122, no. 6, pp. 270-276, 2012.
28. A. Sandoo, T. Dimitroulas, J. J. C. S. Veldhuijzen van Zanten et al., "Lack of association between asymmetric dimethylarginine and in vivo microvascular and macrovascular endothelial function in patients with rheumatoid arthritis," Clinical and Experimental Rheumatology, vol. 30, no. 3, pp. 388-396, 2012.
29. A. Surdacki, J. Martens-Lobenhoffer, A. Wloch et al., "Elevated plasma asymmetric dimethyl-L-arginine levels are linked to endothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis," Arthritis & Rheumatism, vol. 56, no. 3, pp. 809-819, 2007.
30. M. A. Crilly, V. Kumar, H. J. Clark, N. W. Scott, A. G. MacDonald, and D. J. Williams, "Arterial stiffness and cumulative inflammatory burden in rheumatoid arthritis: a dose-response relationship independent of established cardiovascular risk factors," Rheumatology, vol. 48, no. 12, pp. 1606-1612, 2009.
31. Z. Wang, W.H.W. Tang, L. Cho, D. M. Brennan, and S. L. Hazen, "Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potentialmechanisms beyond nitric oxide synthase inhibition," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 9, pp. 1383-1391, 2009.
32. S. Karbach, P. Wenzel, A. Waisman, T. Munzel, and A. Daiber, "eNOS uncoupling in cardiovascular diseases-the role of oxidative stress and inflammation," Current Pharmaceutical Design, vol. 20, no. 22, pp. 3579-3594, 2014.
33. C. Zoccali, R. Maas, S. Cutrupi et al., "Asymmetric dimethylarginine (ADMA) response to inflammation in acute infections," Nephrology Dialysis Transplantation, vol. 22, no. 3, pp. 801-806, 2007.
34. J. T. Kielstein, S. R. Salpeter, S.M. Bode-Boeger, J. P. Cooke, and D. Fliser, "Symmetric dimethylarginine (SDMA) as endogenous marker of renal function-ameta-analysis," Nephrology Dialysis Transplantation, vol. 21, no. 9, pp. 2446-2451, 2006.
35. C. P. Chung, J. T. Giles, M. Petri et al., "Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis," Seminars in Arthritis and Rheumatism, vol. 41, no. 4, pp. 535-544, 2012.
36. L. Innala, B. Möller, L. Ljung et al., "Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study," Arthritis Research & Therapy, vol. 13, no. 4, article R131, 2011.
37. E. E. A. Arts, C. Popa, A. A. Den Broeder et al., "Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis," Annals of the Rheumatic Diseases, vol. 74, no. 4, pp. 668-674, 2015.
38. V. R. da Cunha, C. V. Brenol, J. C. T. Brenol et al., "Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity," Scandinavian Journal of Rheumatology, vol. 41, no. 3, pp. 186-191, 2012.
39. Ö.O. Işi{dotless}klar, B. Barutcuoʇlu, C. Kabaroʇlu et al., "Do cardiac risk factors affect the homocysteine and asymmetric dimethylarginine relationship in patients with coronary artery diseases?" Clinical Biochemistry, vol. 45, no. 16-17, pp. 1325-1330, 2012.
40. P. Wanby, T. Teerlink, L. Brudin et al., "Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population," Atherosclerosis, vol. 185, no. 2, pp. 271-277, 2006.
41. A. Gonzalez, H. M. Kremers, C. S. Crowson et al., "The widening mortality gap between rheumatoid arthritis patients and the general population," Arthritis and Rheumatism, vol. 56, no. 11, pp. 3583-3587, 2007.
42. A. G. Semb, S. Rollefstad, P. L. van Riel, G. D. Kitas, E. L. Matteson, and S. E. Gabriel, "Cardiovascular disease assessment in rheumatoid arthritis: a guide to translating knowledge of cardiovascular risk into clinical practice," Annals in Rheumatic Diseases, vol. 73, no. 7, pp. 1284-1288, 2015.
43. M. A. Martín-Martínez, C. González-Juanatey, S. Castañeda et al., "Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: scientific evidence and expert opinion," Seminars in Arthritis and Rheumatism, vol. 44, no. 1, pp. 1-8, 2014.
44. M. O. Gore, N. Lüneburg, E. Schwedhelm et al., "Symmetrical dimethylarginine predicts mortality in the general population: observations from the dallas heart study," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 11, pp. 2682-2688, 2013.
45. F. R. Spinelli, M. Di Franco, A. Metere et al., "Decrease of asymmetric dimethyl arginine after anti-TNF therapy in patients with rheumatoid arthritis," Drug Development Research, vol. 75, supplement 1, pp. S67-S69, 2014.
46. A. Sandoo, T. Dimitroulas, T. E. Toms et al., "Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patientswith rheumatoid arthritis," Clinical Biochemistry, vol. 45, no. 16-17, pp. 1399-1403, 2012.
47. M. Korkosz, J. Gasowski, A. Surdacki et al., "Disparate effects of anti-TNF-α therapies on measures of disease activity and mediators of endothelial damage in ankylosing spondylitis," Pharmacological Reports, vol. 65, no. 4, pp. 891-897, 2013.